We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Allergy Therapeutics
Biomarker data confirm VLP Peanut hypoallergenicityScancell
CTA approval confirms H221 COVIDITY Phase I startANGLE
First custom CTC assay development contractRedx Pharma
RXC004 2mg dose selected for Phase II trialsRedx Pharma
Rezurock approval has positive read across for RedxAllergy Therapeutics
Strong FY21 trading, but pipeline set to drive futureHUTCHMED
ASCO 2021: Moving towards combinationsHUTCHMED
Hong Kong listing number 13 is a potent symbolAvacta
So much more than a play on COVID testingANGLE
£20m placing to accelerate Parsortix opportunities